Holen Sie sich die Stockscreener-App
0.7147
1.23%
-0.0089
Handel nachbörslich:
.64
-0.0747
-10.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.7236
Offen:
$0.73
24-Stunden-Volumen:
6.88M
Relative Volume:
1.70
Marktkapitalisierung:
$258.36M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.051
EPS:
-0.68
Netto-Cashflow:
$-162.37M
1W Leistung:
-11.80%
1M Leistung:
-11.48%
6M Leistung:
-59.16%
1J Leistung:
-41.42%
1-Tages-Spanne:
$0.7009
$0.76
1-Wochen-Bereich:
$0.6623
$0.8462
52-Wochen-Spanne:
$0.6204
$3.73
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.7147 | 258.36M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com
Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India
Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena
2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga
The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK
Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India
Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights
Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says - Citeline
Lexicon to disband sales team, lay off 60% of staff - BioPharma Dive
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization - MarketWatch
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - The Manila Times
Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - StreetInsider.com
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Appoints Ivan H. Cheung to Board of Directors - The Manila Times
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swain Judith L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| SOBECKI CHRISTOPHER J | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
167,055 |
| LEFKOWITZ ROBERT J MD | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| DEBBANE RAYMOND | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
1,348,879 |
| BARKER SAM L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
87,649 |
| Amouyal Philippe | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
248,364 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):